BR0107282A - Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas - Google Patents

Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas

Info

Publication number
BR0107282A
BR0107282A BR0107282-0A BR0107282A BR0107282A BR 0107282 A BR0107282 A BR 0107282A BR 0107282 A BR0107282 A BR 0107282A BR 0107282 A BR0107282 A BR 0107282A
Authority
BR
Brazil
Prior art keywords
compound
condition
pharmaceutical composition
methods
biological samples
Prior art date
Application number
BR0107282-0A
Other languages
English (en)
Inventor
Bing-Yan Zhu
Ting Su
Wenhao Li
Erick A Goldman
Penglie Zhang
Zhaozhong Jon Jia
Robert M Scarborough
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of BR0107282A publication Critical patent/BR0107282A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA E MéTODOS PARA PREVENIR OU TRATAR UMA CONDIçãO EM UM MAMìFERO E PARA INIBIR A COAGULAçãO DE AMOSTRAS BIOLóGICAS". São descritos novos compostos contendo piperazin-2-ona de fórmulas gerais (I) ou (II), incluindo seus isómeros, sais, hidratos, solvatos farmaceuticamente aceitáveis e derivado de prodroga tendo atividade contra fator Xa mamífero. São também descritas composições contendo tais compostos. Os compostos e as composições são úteis in vitro ou in vivo para prevenir ou tratar condições em mamíferos distinguidas por trombose indesejada.
BR0107282-0A 2000-09-29 2001-10-01 Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas BR0107282A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23639300P 2000-09-29 2000-09-29
PCT/US2001/030313 WO2002026734A1 (en) 2000-09-29 2001-10-01 PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa

Publications (1)

Publication Number Publication Date
BR0107282A true BR0107282A (pt) 2004-07-06

Family

ID=22889303

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107282-0A BR0107282A (pt) 2000-09-29 2001-10-01 Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas

Country Status (7)

Country Link
US (1) US20040072860A1 (pt)
EP (1) EP1322643A1 (pt)
JP (1) JP2004509958A (pt)
AU (1) AU2002211280A1 (pt)
BR (1) BR0107282A (pt)
CA (1) CA2422873A1 (pt)
WO (1) WO2002026734A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US20060178370A1 (en) * 2003-03-18 2006-08-10 Mark Bock Ketopiperazine derivatives as bradykinin antagonists
WO2007008145A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008144A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
GB9715892D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU1692399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
KR20010034442A (ko) * 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제
EP1054005A4 (en) * 1998-02-05 2003-02-05 Takeda Chemical Industries Ltd SULFAMIDE DERIVATIVES, THEIR PRODUCTION PROCESS AND THEIR USE
DE19835950A1 (de) * 1998-08-08 2000-02-10 Merck Patent Gmbh Piperazinonderivate
JP2003529531A (ja) * 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルＸａ因子阻害剤
AU773227B2 (en) * 1999-07-28 2004-05-20 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds

Also Published As

Publication number Publication date
WO2002026734A1 (en) 2002-04-04
CA2422873A1 (en) 2002-04-04
EP1322643A1 (en) 2003-07-02
US20040072860A1 (en) 2004-04-15
JP2004509958A (ja) 2004-04-02
AU2002211280A1 (en) 2002-04-08

Similar Documents

Publication Publication Date Title
NO991700L (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
AU2001250783A1 (en) Benzamides and related inhibitors of factor xa
BR9814340A (pt) Derivados de indol como inibidores de fator xa
EA200201277A1 (ru) Замещенные бициклические производные для лечения аномального роста клеток
BR0005633A (pt) Derivados de quinolina úteis para inibição da farnesil proteìna transferase
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
IL155155A0 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
BR0014078A (pt) Inibidores de fator xa
NO20003514L (no) Hypolipidemiske benzothiazepin-forbindelser
PT928788E (pt) Compostos farmaceuticamente activos
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
WO2001072708A3 (en) OXINDOLE INHIBITORS OF FACTOR Xa
ATE150301T1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen
WO2002026720A3 (en) PIPERAZINE BASED INHIBITORS OF FACTOR Xa
BR0107282A (pt) Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas
BR9814376A (pt) Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &4ß1, e, resina
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal
ATE273277T1 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
BR9910628A (pt) Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]